NEWARK, Calif., Feb. 10, 2022 /PRNewswire/ -- Protagonist
Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company")
today announced that Dinesh V.
Patel, Ph.D., President and Chief Executive Officer, will
present virtually at the 11th Annual SVB Leerink Global Healthcare
Conference on February 17th at
3:00 p.m. EST.
A live and archived webcast of the event will be available in
the Investors section of the Protagonist Therapeutics website at
https://investors.protagonist-inc.com/.
About Protagonist
Protagonist Therapeutics is a biopharmaceutical company with
multiple peptide-based new chemical entities in different stages of
clinical development, all derived from the Company's proprietary
technology platform.
Protagonist's pipeline includes rusfertide, an investigational,
injectable hepcidin mimetic currently in the REVIVE Phase 2
proof-of-concept clinical trial for polycythemia vera (PV), the
PACIFIC Phase 2 study in PV subjects with high hematocrit levels,
and a recently completed Phase 2a study for hereditary
hemochromatosis. The Company is actively initiating PERSIST, a
single, global Phase 3 randomized, placebo-controlled trial
evaluating the efficacy and safety of a once weekly, subcutaneously
self-administered dose of rusfertide.
The Company is also evaluating an orally delivered,
gut-restricted alpha-4-beta-7 integrin specific antagonist peptide
(PN-943), currently in the IDEAL Phase 2 study in adults with
moderate to severe active ulcerative colitis (UC). The Company is
targeting ulcerative colitis as the initial indication.
The Company has a worldwide license and collaboration agreement
with Janssen Biotech, Inc., for the development of oral peptide
IL-23 receptor antagonist PN-235 (JNJ-77242113), a
second-generation oral interleukin-23 receptor antagonist
candidate. Under the collaboration with Janssen, PN-235 is expected
to advance into Phase 2b studies in
psoriasis and at least one new Phase 2 clinical study in
inflammatory bowel disease.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-11th-annual-svb-leerink-global-healthcare-conference-301479454.html
SOURCE Protagonist Therapeutics, Inc.